BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 33997102)

  • 1. Genetically blocking
    Gu P; Yang Q; Chen B; Bie YN; Liu W; Tian Y; Luo H; Xu T; Liang C; Ye X; Liu Y; Tang X; Gu W
    Mol Ther Methods Clin Dev; 2021 Jun; 21():530-547. PubMed ID: 33997102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An engineered Escherichia coli Nissle strain prevents lethal liver injury in a mouse model of tyrosinemia type 1.
    Gu P; Xie L; Chen T; Yang Q; Zhang X; Liu R; Guo J; Wei R; Li D; Jiang Y; Chen Y; Gong W; Chen P
    J Hepatol; 2024 Mar; 80(3):454-466. PubMed ID: 37952766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A mouse model of renal tubular injury of tyrosinemia type 1: development of de Toni Fanconi syndrome and apoptosis of renal tubular cells in Fah/Hpd double mutant mice.
    Sun MS; Hattori S; Kubo S; Awata H; Matsuda I; Endo F
    J Am Soc Nephrol; 2000 Feb; 11(2):291-300. PubMed ID: 10665936
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ex vivo gene editing and cell therapy for hereditary tyrosinemia type 1.
    Ates I; Stuart C; Rathbone T; Barzi M; He G; Major AM; Shankar V; Lyman RA; Angner SS; Mackay TFC; Srinivasan S; Farris AB; Bissig KD; Cottle RN
    Hepatol Commun; 2024 May; 8(5):. PubMed ID: 38668730
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Curative Ex Vivo Hepatocyte-Directed Gene Editing in a Mouse Model of Hereditary Tyrosinemia Type 1.
    VanLith C; Guthman R; Nicolas CT; Allen K; Du Z; Joo DJ; Nyberg SL; Lillegard JB; Hickey RD
    Hum Gene Ther; 2018 Nov; 29(11):1315-1326. PubMed ID: 29764210
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Complete rescue of lethal albino c14CoS mice by null mutation of 4-hydroxyphenylpyruvate dioxygenase and induction of apoptosis of hepatocytes in these mice by in vivo retrieval of the tyrosine catabolic pathway.
    Endo F; Kubo S; Awata H; Kiwaki K; Katoh H; Kanegae Y; Saito I; Miyazaki J; Yamamoto T; Jakobs C; Hattori S; Matsuda I
    J Biol Chem; 1997 Sep; 272(39):24426-32. PubMed ID: 9305902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficient liver repopulation of transplanted hepatocyte prevents cirrhosis in a rat model of hereditary tyrosinemia type I.
    Zhang L; Shao Y; Li L; Tian F; Cen J; Chen X; Hu D; Zhou Y; Xie W; Zheng Y; Ji Y; Liu M; Li D; Hui L
    Sci Rep; 2016 Aug; 6():31460. PubMed ID: 27510266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models reveal pathophysiologies of tyrosinemias.
    Endo F; Tanaka Y; Tomoeda K; Tanoue A; Tsujimoto G; Nakamura K
    J Nutr; 2003 Jun; 133(6 Suppl 1):2063S-2067S. PubMed ID: 12771366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fumarylacetoacetate hydrolase deficient pigs are a novel large animal model of metabolic liver disease.
    Hickey RD; Mao SA; Glorioso J; Lillegard JB; Fisher JE; Amiot B; Rinaldo P; Harding CO; Marler R; Finegold MJ; Grompe M; Nyberg SL
    Stem Cell Res; 2014 Jul; 13(1):144-53. PubMed ID: 24879068
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CRISPR/Cas9-Mediated Gene Correction in Newborn Rabbits with Hereditary Tyrosinemia Type I.
    Li N; Gou S; Wang J; Zhang Q; Huang X; Xie J; Li L; Jin Q; Ouyang Z; Chen F; Ge W; Shi H; Liang Y; Zhuang Z; Zhao X; Lian M; Ye Y; Quan L; Wu H; Lai L; Wang K
    Mol Ther; 2021 Mar; 29(3):1001-1015. PubMed ID: 33221434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Autologous Gene and Cell Therapy Provides Safe and Long-Term Curative Therapy in A Large Pig Model of Hereditary Tyrosinemia Type 1.
    Hickey RD; Nicolas CT; Allen K; Mao S; Elgilani F; Glorioso J; Amiot B; VanLith C; Guthman R; Du Z; Chen H; Harding CO; Kaiser RA; Nyberg SL; Lillegard JB
    Cell Transplant; 2019 Jan; 28(1):79-88. PubMed ID: 30477316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cas9-nickase-mediated genome editing corrects hereditary tyrosinemia in rats.
    Shao Y; Wang L; Guo N; Wang S; Yang L; Li Y; Wang M; Yin S; Han H; Zeng L; Zhang L; Hui L; Ding Q; Zhang J; Geng H; Liu M; Li D
    J Biol Chem; 2018 May; 293(18):6883-6892. PubMed ID: 29507093
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The compound heterozygous mutations of c.607G>a and c.657delC in the FAH gene are associated with renal damage with hereditary tyrosinemia type 1 (HT1).
    Chi H; Gan C; Jiang Y; Chen D; Qiu J; Yang Q; Chen Y; Wang M; Yang H; Jiang W; Li Q
    Mol Genet Genomic Med; 2023 Jan; 11(1):e2090. PubMed ID: 36369907
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biochemical and Clinical Aspects of Hereditary Tyrosinemia Type 1.
    Morrow G; Tanguay RM
    Adv Exp Med Biol; 2017; 959():9-21. PubMed ID: 28755181
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatocyte injury in tyrosinemia type 1 is induced by fumarylacetoacetate and is inhibited by caspase inhibitors.
    Kubo S; Sun M; Miyahara M; Umeyama K; Urakami K; Yamamoto T; Jakobs C; Matsuda I; Endo F
    Proc Natl Acad Sci U S A; 1998 Aug; 95(16):9552-7. PubMed ID: 9689118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curative ex vivo liver-directed gene therapy in a pig model of hereditary tyrosinemia type 1.
    Hickey RD; Mao SA; Glorioso J; Elgilani F; Amiot B; Chen H; Rinaldo P; Marler R; Jiang H; DeGrado TR; Suksanpaisan L; O'Connor MK; Freeman BL; Ibrahim SH; Peng KW; Harding CO; Ho CS; Grompe M; Ikeda Y; Lillegard JB; Russell SJ; Nyberg SL
    Sci Transl Med; 2016 Jul; 8(349):349ra99. PubMed ID: 27464750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic Phenotype Characterization of a Large-Animal Model of Hereditary Tyrosinemia Type 1.
    Elgilani F; Mao SA; Glorioso JM; Yin M; Iankov ID; Singh A; Amiot B; Rinaldo P; Marler RJ; Ehman RL; Grompe M; Lillegard JB; Hickey RD; Nyberg SL
    Am J Pathol; 2017 Jan; 187(1):33-41. PubMed ID: 27855279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rescue of mice homozygous for lethal albino deletions: implications for an animal model for the human liver disease tyrosinemia type 1.
    Kelsey G; Ruppert S; Beermann F; Grund C; Tanguay RM; Schütz G
    Genes Dev; 1993 Dec; 7(12A):2285-97. PubMed ID: 8253377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatic stress in hereditary tyrosinemia type 1 (HT1) activates the AKT survival pathway in the fah-/- knockout mice model.
    Orejuela D; Jorquera R; Bergeron A; Finegold MJ; Tanguay RM
    J Hepatol; 2008 Feb; 48(2):308-17. PubMed ID: 18093685
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Molecular Aspects of the FAH Mutations Involved in HT1 Disease.
    Morrow G; Angileri F; Tanguay RM
    Adv Exp Med Biol; 2017; 959():25-48. PubMed ID: 28755182
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.